Event:
Location:
One-on-one meetings:
Participants:
Event: Piper Sandler 35th Healthcare Conference
Location:
Fireside chat:
Presenter:
Webcast link: https://event.webcasts.com/starthere.jsp?ei=1643140&tp_key=1d3631cba2
A webcast replay of the presentations will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation.
About
About IO102-IO103
IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced non-small cell lung cancer and head and neck cancer (SCCHN), and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) evaluating IO102-IO103 plus pembrolizumab as a perioperative treatment in solid tumors including melanoma and SCCHN.
The clinical trials are sponsored by
KEYTRUDA® is a registered trademark of
For further information, please visit www.iobiotech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim analysis of our Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law,
Contact:
617-710-7305
mci@iobiotech.com
![](https://ml.globenewswire.com/media/MWY5ZTIyNmItNGZmMi00NzRiLWFmYmQtNTM2MWFmMzA1NDA1LTEyNzMwMzE=/tiny/IO-Biotech.png)
2023 GlobeNewswire, Inc., source